Signaturefd LLC Lowers Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Signaturefd LLC reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 25.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,030 shares of the medical research company’s stock after selling 343 shares during the quarter. Signaturefd LLC’s holdings in Charles River Laboratories International were worth $243,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. VisionPoint Advisory Group LLC boosted its stake in Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after buying an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at $37,000. Operose Advisors LLC bought a new position in shares of Charles River Laboratories International during the 3rd quarter valued at $42,000. Venturi Wealth Management LLC raised its position in Charles River Laboratories International by 74.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after purchasing an additional 112 shares during the period. Finally, Provence Wealth Management Group purchased a new position in Charles River Laboratories International in the 3rd quarter worth $57,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Up 0.5 %

Shares of CRL opened at $229.03 on Friday. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. The firm’s 50-day moving average price is $253.48 and its 200-day moving average price is $222.64. The firm has a market capitalization of $11.80 billion, a price-to-earnings ratio of 24.87, a PEG ratio of 1.88 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. During the same period in the previous year, the firm posted $2.98 EPS. The business’s revenue was down 7.9% on a year-over-year basis. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares of the company’s stock, valued at $626,155.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares in the company, valued at $626,155.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Victoria L. Creamer sold 5,000 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares of the company’s stock, valued at $3,437,635. The disclosure for this sale can be found here. Insiders have sold a total of 14,932 shares of company stock valued at $3,693,663 over the last ninety days. Company insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CRL. TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. UBS Group boosted their price objective on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Citigroup increased their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. Finally, Robert W. Baird upped their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $253.23.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).